Path to Improved Risk Stratification
改进风险分层的途径
基本信息
- 批准号:9125490
- 负责人:
- 金额:$ 1.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAreaAttentionBostonCessation of lifeChicagoClinicalClinical TrialsCollaborationsCommunicationDevelopmentDistrict of ColumbiaEconomicsEpidemiologyEthicsEventFosteringGoalsGovernment AgenciesHealth Care ResearchHealthcareHeart ArrestHospitalsIndividualIndustryInstitutesInsuranceInvestmentsKnowledgeMinorityMissionNational Heart, Lung, and Blood InstituteParticipantPatientsPhysiciansPreventionPrevention strategyProfessional OrganizationsPublic HealthReportingResearchResearch PersonnelResuscitationRiskSaint Jude Children&aposs Research HospitalScientistStratificationTechniquesTeleconferencesTestingThinkingTimeUnited StatesUnited States Agency for Healthcare Research and QualityUnited States Centers for Medicare and Medicaid ServicesUnited States Food and Drug AdministrationUpdateWashingtonWomanWorkbasedesignexperiencehealth care qualityhealth economicsheuristicsimprovedinnovationinterestknowledge basemeetingsmembersoundsuccesssudden cardiac deathsymposiumtool
项目摘要
DESCRIPTION (provided by applicant): Sudden cardiac death is a major public health problem with approximately 180,000 to 400,000 deaths annually. Because of the low efficacy and success rates of out-of-hospital resuscitation, a high priority has been set to try and identif individuals at risk for sudden cardiac death prior to the event. If this can be done, there are treatments that can be instituted to mitigate this risk. However, despite decades of research, and significant investments of time, effort, and research dollars, there is not yet an ideal or eve acceptable approach to risk stratification for sudden cardiac death. One approach that could be initiated to engender more rapid progress in this area is to promote better coordination among the various stakeholders - investigators, government agencies, and industry. Although all are vested in the need for risk stratification, each group has different sets of priorities and therefoe approaches the problem from different perspectives. The Path to Improved Risk Stratification, NFP is a not-for-profit think tank founded by Dr. Jeffrey Goldberger whose mission is to serve as a focal point to help organize a rational, coordinated plan for developing, evaluating, and implementing risk stratification strategies for prevention of sudden cardiac death. The Path to Improved Risk Stratification, NFP has organized annual single day meetings in Chicago from 2005-2012 and in Washington in 2014 and 2015 with: 1) physician leaders in the area of risk stratification, clinical trials in prevention of sudden cardiac death, epidemiology, and health economics; 2) representatives from the relevant government agencies; 3) representatives from industry. The meeting agendas are designed to identify important gaps in our knowledge and to strategize how those gaps can best be filled. These meetings have resulted in new efforts in risk stratification and have helped guide some clinical trials that have been in development. The agenda for each meeting is to evaluate progress from the prior meeting, review new information relevant to risk stratification, discuss issues related to ongoing clinical trials, obtain updates n planning of new trials, review scientific/statistical/economics issues related to risk stratificatin, and explore new areas that are gaps in our knowledge base. Having identified the gaps, there is now greater emphasis on developing an action plan to address some of the identified gaps. Given the vastness of the information that needs to be understood to advance the field of risk stratification, this effort provides an important sounding board for those involved and encourages collaboration and the development of innovative approaches.
Narrative: The Path to Improved Risk Stratification for Sudden Cardiac Death conference is a think tank of multiple stakeholders interested in improving our ability to identify patients at ris for sudden cardiac death prior to suffering this event. As this is a major public health problem, leading to approximately 180000 to 400000 deaths annually, a collaborative effort is necessary to overcome the barriers to advancement in this field.
描述(由申请人提供):心源性猝死是一个重大的公共卫生问题,每年约有 180,000 至 400,000 人死亡,由于院外复苏的有效性和成功率较低,因此已将尝试和识别列为高度优先事项。如果可以做到这一点,就可以采取一些治疗措施来减轻这种风险,但是,尽管进行了数十年的研究,但效果显着。尽管投入了大量的时间、精力和研究资金,但目前还没有一种理想的甚至可接受的方法来对心源性猝死进行风险分层,可以采取的一种方法是促进各个方面之间更好的协调,从而在这一领域取得更快的进展。尽管所有利益相关者都需要进行风险分层,但每个群体都有不同的优先事项,因此从不同的角度处理问题,但 NFP 并不适用。 - 利润智囊团成立由杰弗里·戈德伯格 (Jeffrey Goldberger) 博士主持,他的使命是帮助组织合理、协调的计划,以制定、评估和实施预防心源性猝死的风险分层策略,NFP 组织了年度活动。 2005 年至 2012 年在芝加哥以及 2014 年和 2015 年在华盛顿举行的单日会议,与会者包括:1) 风险分层、预防心源性猝死临床试验领域的医生领导者,流行病学和卫生经济学;2)相关政府机构的代表;3)行业代表的会议议程旨在确定我们的知识差距并制定如何最好地填补这些差距的战略。风险分层方面的努力,并帮助指导了一些正在开发的临床试验。每次会议的议程是评估上次会议的进展,审查与风险分层相关的新信息,讨论与正在进行的临床试验相关的问题,获取最新信息。规划新的试验,审查与风险分层相关的科学/统计/经济学问题,并探索我们知识库中存在的差距。在确定了差距之后,现在更加重视制定行动计划来解决一些已确定的差距。推进风险分层领域需要理解大量信息,这一努力为相关人员提供了重要的参谋,并鼓励合作和创新方法的开发。
叙述:改善心源性猝死风险分层的途径会议是一个由多个利益相关者组成的智囊团,致力于提高我们在遭受心源性猝死事件之前识别处于危险状态的患者的能力,因为这是一个重大的公共卫生问题,导致。每年约有 180,000 至 400,000 人死亡,因此需要共同努力克服该领域进步的障碍。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future.
扩张型心肌病猝死的个性化风险分层:过去、现在和未来。
- DOI:
- 发表时间:2017-07-11
- 期刊:
- 影响因子:37.8
- 作者:Halliday, Brian P;Cleland, John G F;Goldberger, Jeffrey J;Prasad, Sanjay K
- 通讯作者:Prasad, Sanjay K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY J GOLDBERGER其他文献
JEFFREY J GOLDBERGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY J GOLDBERGER', 18)}}的其他基金
Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns
心房颤动电图模式的病理生理学意义
- 批准号:
10634983 - 财政年份:2023
- 资助金额:
$ 1.2万 - 项目类别:
Trans-omic analysis of epicardial adipose tissue in atrial fibrillation
心房颤动心外膜脂肪组织的跨组学分析
- 批准号:
10553649 - 财政年份:2021
- 资助金额:
$ 1.2万 - 项目类别:
Trans-omic analysis of epicardial adipose tissue in atrial fibrillation
心房颤动心外膜脂肪组织的跨组学分析
- 批准号:
10096986 - 财政年份:2021
- 资助金额:
$ 1.2万 - 项目类别:
Trans-omic analysis of epicardial adipose tissue in atrial fibrillation
心房颤动心外膜脂肪组织的跨组学分析
- 批准号:
10330560 - 财政年份:2021
- 资助金额:
$ 1.2万 - 项目类别:
Novel medical adjunctive therapy to catheter ablation for atrial fibrillation
心房颤动导管消融的新型医学辅助疗法
- 批准号:
10113417 - 财政年份:2019
- 资助金额:
$ 1.2万 - 项目类别:
4D Magnetic Resonance Imaging for Atrial Flow Assessment in Atrial Fibrillation
4D 磁共振成像用于心房颤动心房血流评估
- 批准号:
8445112 - 财政年份:2013
- 资助金额:
$ 1.2万 - 项目类别:
4D Magnetic Resonance Imaging for Atrial Flow Assessment in Atrial Fibrillation
4D 磁共振成像用于心房颤动心房血流评估
- 批准号:
8605912 - 财政年份:2013
- 资助金额:
$ 1.2万 - 项目类别:
相似国自然基金
多区域环境因素复杂暴露反应关系的空间联合估计方法研究
- 批准号:82373689
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
区域出口产品升级的时空格局及机制研究——以粤港澳大湾区为例
- 批准号:42301182
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多入口下穿隧道合流区域交通事故演化机理与自解释调控方法
- 批准号:52302437
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
应对多重不确定性的区域综合能源系统分布渐进调度理论研究
- 批准号:52377108
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
异质性视角下稻米区域公用品牌价值攀升协同治理机制研究
- 批准号:72373129
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 1.2万 - 项目类别:
Mechanism of epidermal coordination during development and regeneration in zebrafish
斑马鱼发育和再生过程中表皮协调机制
- 批准号:
10643060 - 财政年份:2023
- 资助金额:
$ 1.2万 - 项目类别:
Gabapentinoid/opioid mixtures: abuse and toxicity
加巴喷丁/阿片类混合物:滥用和毒性
- 批准号:
10639396 - 财政年份:2023
- 资助金额:
$ 1.2万 - 项目类别: